Evolution of neuronal and glial tau isoforms in Chronic Traumatic Encephalopathy (CTE)
3 Nov 2020
In this video, Dr. Jonathan Cherry, Assistant Professor of Pathology and Laboratory Medicine at Boston University, speaks about how the opal staining platform and the Vectra Polaris imaging system enabled him to study the immune profile of diseased brain tissue, a historically challenging tissue type in terms of autofluorescence. Specifically, Dr. Jon Cherry discusses his work studying the evolution of neuronal and glial tau isoforms in Chronic Traumatic Encephalopathy.
About the company
Akoya Biosciences
Akoya Biosciences, 'The Spatial Biology Company', is committed to developing powerful imaging tools to enable scientists and clinical researchers gain a better understanding of complex diseases such as cancer. The company offers the most comprehensive end-to-end solution for high-parameter tissue analysis from discovery through clinical and translational research, enabling more precise therapies for immuno-oncology and other drug development applications. Akoya’s CODEX platform enables the assessment of more than 40 markers and is ideally suited for biomarker discovery. The company’s Phenoptics platform provides the assay robustness and throughput necessary for translational and clinical research required in clinical trials.
Related products
Request Quote for All Products
PhenoImager® HT
Akoya BiosciencesPhenoImager ® HT (formerly Vectra ® Polaris™) is the fastest and most highly cited whole-slide, single-cell resolution imaging platform for spatial phenotyping and the development of spatial signatures. Featuring Akoya’s patented Multispectral Imaging (MSI) and spectral unmixing technologies, this platform can be easily integrated into high-throughput workflows to accommodate projects regardless of your scale.
